NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $7.00 -0.02 (-0.28%) Closing price 04:00 PM EasternExtended Trading$5.70 -1.30 (-18.56%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Tevogen Bio Stock (NASDAQ:TVGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$6.73▼$7.0950-Day Range$3.89▼$11.6752-Week Range$3.64▼$69.99Volume9,085 shsAverage Volume26,246 shsMarket Capitalization$29.54 millionP/E RatioN/ADividend YieldN/APrice Target$100.00Consensus RatingReduce Company Overview Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML). In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections. Its research and development efforts seek to harness both non-engineered and engineered NK cells, including chimeric antigen receptor (CAR) NK constructs, to address a broad range of diseases. The company’s technology platform is protected by patents covering manufacturing processes and product compositions. Founded in 2013 by a team of immunotherapy experts, Tevogen Bio maintains research facilities in the United States, Israel and Denmark. Under the leadership of co-founder and Chief Executive Officer Khurshid Guru, the company has progressed from early-stage discovery to clinical development. It is actively expanding its manufacturing capabilities to support late-stage trials and future commercialization efforts. Tevogen Bio collaborates with academic institutions and drug development partners to accelerate its pipeline. The company engages with regulatory authorities in North America and Europe as it advances clinical programs and prepares for potential market entry. By focusing on the innate immune system and personalized therapeutic approaches, Tevogen Bio aims to address unmet medical needs in oncology and viral disease treatment.AI Generated. May Contain Errors. Read More Tevogen Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreTVGN MarketRank™: Tevogen Bio scored higher than 28% of companies evaluated by MarketBeat, and ranked 772nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingTevogen Bio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTevogen Bio has a consensus price target of $100.00, representing about 1,344.0% upside from its current price of $6.93.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tevogen Bio is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tevogen Bio is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Tevogen Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.25% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently decreased by 0.83%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tevogen Bio this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Tevogen Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have not sold or bought any company stock.Percentage Held by Insiders70.51% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTevogen Bio has minimal institutional ownership at this time.Read more about Tevogen Bio's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGN Stock News HeadlinesTevogen Bio Holdings Rebrands as Tevogen Inc.July 30, 2026 | tipranks.comTevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGNJuly 24, 2026 | benzinga.comNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.August 4 at 1:00 AM | Brownstone Research (Ad)Tevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10, 2026 | finanznachrichten.deTevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9, 2026 | quiverquant.comQTevogen Announces Formation of a Healthcare Services InitiativeJune 9, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $16.5550 at the beginning of the year. Since then, TVGN shares have decreased by 58.2% and is now trading at $6.9250. How were Tevogen Bio's earnings last quarter? Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its earnings results on Friday, May, 15th. The company reported ($1.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.64) by $1.03. When did Tevogen Bio's stock split? Shares of Tevogen Bio reverse split on the morning of Friday, March 6th 2026.The 1-50 reverse split was announced on Wednesday, March 4th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tevogen Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tevogen Bio investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings5/15/2026Today8/04/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 8 days, TVGN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Tevogen Bio$100.00 High Price Target$100.00 Low Price Target$100.00 Potential Upside/Downside+1,328.6%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.27 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-472.77% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($211.84) per share Price / Book-0.03Miscellaneous Outstanding Shares4,220,000Free Float1,244,000Market Cap$29.54 million OptionableN/A Beta0.18 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:TVGN) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our Partners"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredDon't download this book (seriously)Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored[URGENT] Mode Mobile terms changing Aug 14Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors...Mode Mobile | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
